Cargando…
Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039803/ http://dx.doi.org/10.1038/sj.bjc.6606043 |
| _version_ | 1782198235434057728 |
|---|---|
| author | Feliu, J Barriuso, J |
| author_facet | Feliu, J Barriuso, J |
| author_sort | Feliu, J |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-3039803 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2011 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-30398032012-01-04 Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliu, J Barriuso, J Br J Cancer Letter to the Editor Nature Publishing Group 2011-01-04 2010-12-14 /pmc/articles/PMC3039803/ http://dx.doi.org/10.1038/sj.bjc.6606043 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Feliu, J Barriuso, J Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title | Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_full | Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_fullStr | Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_full_unstemmed | Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_short | Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| title_sort | reply: capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039803/ http://dx.doi.org/10.1038/sj.bjc.6606043 |
| work_keys_str_mv | AT feliuj replycapecitabineandbevacizumabasfirstlinetreatmentinelderlypatientswithmetastaticcolorectalcancer AT barriusoj replycapecitabineandbevacizumabasfirstlinetreatmentinelderlypatientswithmetastaticcolorectalcancer |